VIDEO: Three trials reinforce positive results of MacTel treatment

ByW. Lloyd Clark, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.

Compared with sham, patients implanted with NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals) for macular telangiectasia (MacTel) experienced less ellipsoid zone loss, a reduction in the loss of reading speed and an “excellent” treatment response based on macular perimetry, according to Clark.

As Healio previously reported, NT-501 for MacTel has a Prescription Drug User Fee Act date of March 18.

Published by:

Sources/Disclosures

Collapse

Source:

Clark WL, et al. Pooled functionality data of revakinagene taroretcel in patients with macular telangiectasia type 2. Presented at: Hawaiian Eye 2025; Jan. 18-24, 2025; Koloa, Hawaii.

Disclosures: Clark reports being a consultant and investigator for Neurotech.

Read more about

macular telangiectasia

retina

cell therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment